Elevation Oncology Stock Price To Book
| ELEV Stock | USD 0.55 0.03 5.77% |
Elevation Oncology fundamentals help investors to digest information that contributes to Elevation Oncology's financial success or failures. It also enables traders to predict the movement of Elevation Stock. The fundamental analysis module provides a way to measure Elevation Oncology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Elevation Oncology stock.
Price To Book Ratio is likely to climb to 0.35 in 2024. Elevation | Price To Book |
Elevation Oncology Company Price To Book Analysis
Elevation Oncology's Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Current Elevation Oncology Price To Book | 0.38 X |
Most of Elevation Oncology's fundamental indicators, such as Price To Book, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Elevation Oncology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Elevation Price To Book Driver Correlations
Understanding the fundamental principles of building solid financial models for Elevation Oncology is extremely important. It helps to project a fair market value of Elevation Stock properly, considering its historical fundamentals such as Price To Book. Since Elevation Oncology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Elevation Oncology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Elevation Oncology's interrelated accounts and indicators.
Click cells to compare fundamentals
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
| Competition |
Elevation Book Value Per Share
Book Value Per Share |
|
Based on the latest financial disclosure, Elevation Oncology has a Price To Book of 0.3825 times. This is 98.51% lower than that of the Biotechnology sector and 93.67% lower than that of the Health Care industry. The price to book for all United States stocks is 95.98% higher than that of the company.
Elevation Price To Book Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Elevation Oncology's direct or indirect competition against its Price To Book to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Elevation Oncology could also be used in its relative valuation, which is a method of valuing Elevation Oncology by comparing valuation metrics of similar companies.Elevation Oncology is currently under evaluation in price to book category among its peers.
Elevation Fundamentals
| Return On Equity | -0.52 | ||||
| Return On Asset | -0.22 | ||||
| Current Valuation | (49.27 M) | ||||
| Shares Outstanding | 59.11 M | ||||
| Shares Owned By Insiders | 0.20 % | ||||
| Shares Owned By Institutions | 99.64 % | ||||
| Number Of Shares Shorted | 6.15 M | ||||
| Price To Earning | 0.16 X | ||||
| Price To Book | 0.38 X | ||||
| EBITDA | (40.3 M) | ||||
| Net Income | (45.7 M) | ||||
| Cash And Equivalents | 122.54 M | ||||
| Cash Per Share | 5.26 X | ||||
| Total Debt | 30.14 M | ||||
| Current Ratio | 6.48 X | ||||
| Book Value Per Share | 1.48 X | ||||
| Cash Flow From Operations | (56.18 M) | ||||
| Short Ratio | 8.09 X | ||||
| Earnings Per Share | (0.68) X | ||||
| Target Price | 7.5 | ||||
| Number Of Employees | 29 | ||||
| Beta | 1.24 | ||||
| Market Capitalization | 30.68 M | ||||
| Total Asset | 89.09 M | ||||
| Retained Earnings | (195.97 M) | ||||
| Working Capital | 83.82 M | ||||
| Net Asset | 89.09 M |
About Elevation Oncology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Elevation Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Elevation Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Elevation Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Elevation Stock Analysis
When running Elevation Oncology's price analysis, check to measure Elevation Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elevation Oncology is operating at the current time. Most of Elevation Oncology's value examination focuses on studying past and present price action to predict the probability of Elevation Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elevation Oncology's price. Additionally, you may evaluate how the addition of Elevation Oncology to your portfolios can decrease your overall portfolio volatility.